NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
658
1,169
1,810
21,970
13,249
Cost of Revenue
29
97
4
2,297
1,755
Gross Profit
628
1,073
1,807
19,673
11,495
Operating Expenses
Research Development
4,467
4,222
4,514
8,883
12,788
Selling General and Administrative
6,553
7,698
11,170
13,014
17,257
Total Operating Expenses
11,020
11,920
15,684
21,896
30,045
Operating Income or Loss
-10,392
-10,847
-13,877
-2,223
-18,551
Interest Expense
-
31
-
-
-
Total Other Income/Expenses Net
-1,033
-5,290
-4,082
2,776
-3,334
Income Before Tax
-11,412
-16,169
-17,790
-14,309
-28,758
Income Tax Expense
-74
-10
-4,062
-
-436
Income from Continuing Operations
-11,337
-16,159
-13,727
-14,309
-28,322
Net Income
-11,337
-16,114
74,946
-14,308
-27,563
Net Income available to common shareholders
-11,337
-16,114
74,946
-14,308
-27,609
Reported EPS
Basic
-
-1.80
9.40
-1.80
-3.60
Diluted
-
-1.80
9.00
-1.80
-3.60
Weighted average shares outstanding
Basic
-
8,527
8,080
7,771
7,559
Diluted
-
8,527
8,301
7,771
7,559
EBITDA
-
-10,697
-13,622
-1,722
-17,979